Real-world study of niraparib for ovarian cancer after initial treatment
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at how well niraparib works as maintenance therapy for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have already responded to initial chemotherapy. It aims to gather real-world data on the treatment's effectiveness and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have high-grade serous or high-grade endometrioid ovarian, fallopian tube, or primary peritoneal cancer.
- You received only one prior line of platinum-based chemotherapy and had a complete or partial response.
- You are now receiving niraparib as maintenance therapy in everyday clinical practice.
- You do not have other serious medical conditions that would make the treatment unsafe.
- You are not being treated for another cancer, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the drug niraparib works as a maintenance treatment for women with advanced ovarian cancer that responded well to initial platinum-based chemotherapy. It may help keep the cancer from coming back.
This trial is testing a second course of niraparib (a PARP inhibitor) after surgery for ovarian cancer that has come back in just a few spots. It aims to see if restarting niraparib can help keep the cancer from coming back again.
This trial tests whether a different starting dose (and adjustments) of niraparib can help people with advanced ovarian (or related) cancer stay on treatment without as many dose interruptions. It’s designed for people who have already finished first-line chemotherapy and whose cancer responded.
This trial tests whether taking niraparib (a maintenance anti-cancer pill) for a shorter time after 3 cycles of platinum chemotherapy works as well as taking it after 6 cycles. It is for people with advanced ovarian cancer that has been fully removed (no visible tumor) and is “HRD-positive,” meaning it has certain DNA repair weaknesses.
This trial tests a new maintenance therapy called niraparib for Black women who have finished initial treatment for advanced ovarian cancer and are in remission or partial response. It aims to see if the drug is safe and how your body processes it.
This trial studies whether niraparib works better when combined with bevacizumab after chemotherapy and surgery for advanced ovarian, fallopian tube, or peritoneal cancer. If you qualify, you may help researchers find a treatment plan that controls the cancer for longer.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.